and Lung Cancer Targets: Cyclin Dependent Kinase (CDKs) inhibitors, Platelet Derived Growth Factor
(PDGF) inhibitors and many more.
today announced an agreement to jointly develop an innovative antibody to Platelet Derived Growth Factor
Receptor Beta (PDGFR-?
At the end of the 21-day experimental period, arterial sections were evaluated histomorphologically and immunohistochemically with staining using antibodies against platelet derived growth factor
[beta] and basic fibroblast growth factor.
platelet derived growth factor
receptor protein which preferentially binds to the AA homodimer and AB heterodimer forms of platelet derived growth factor
and also binds the BB homodimer at high affinity, is described.
ULURU will present research on the combination of our Nanoflex-technology system based wound dressing incorporating the delivery of platelet derived growth factor
Platelet Derived Growth Factor
(PDGF)--PDGF is a very powerful regulatory growth factor and a sentinel growth factor that begins nearly all wound healing.
University of California (Oakland, CA) has patented compounds which can inhibit platelet derived growth factor
receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family.
The Canadian patent will contain 200 claims covering compositions and methods of using recombinant platelet derived growth factor
(rhPDGF-BB) combined with various matrix materials having defined characteristics.
This patent will cover methods of treating impaired bone to facilitate strengthening and healing of bone using novel compositions of recombinant human platelet derived growth factor
(rhPDGF-BB) combined with matrix materials having defined characteristics.
Such molecules may include nerve growth factor, motor proteins, platelet derived growth factor
, tubulin, neurofilaments, calmodulin, microtubule associated protein, interferon and others.
NASDAQ: BMTI) today announced that it has received orphan drug designation from the Food and Drug Administration (FDA) for its protein therapeutic, recombinant human platelet derived growth factor
(rhPDGF-BB), to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans (OCD) of the knee, elbow or ankle.
The allowed claims cover compositions of platelet derived growth factor
(PDGF) combined with matrix materials having defined characteristics, which cover the Company's novel recombinant protein-device combination product candidates, including Augment[TM] Bone Graft and Augment[TM] Injectable Bone Graft, as well as GEMESIS([TM]), which the Company previously sold to Luitpold Pharmaceuticals, Inc.